GNH USA

Europe — EMA

Pamorelin La (Triptorelin)

GNH USA supplies Pamorelin La (Triptorelin), a GnRH agonist for prostate cancer, endometriosis and IVF protocols. Request a quote for global supply.

Triptorelin

Request sourcing

1
Pack/s

What is Triptorelin?

Triptorelin, the active ingredient in Pamorelin La, is a gonadotropin-releasing hormone (GnRH) agonist presented as a sterile powder for solution for injection use. It is employed in the management of hormone‑dependent conditions such as prostate cancer, endometriosis and assisted reproductive protocols in adults. GNH USA supplies Pamorelin La as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

What is Triptorelin used for?

Pamorelin La (triptorelin) acts on the gonadotropin‑releasing hormone pathway and is indicated for several hormone‑dependent conditions. - Prostate cancer: provides hormonal suppression to slow disease progression. - Endometriosis: reduces pelvic pain and lesion growth by lowering estrogen levels. - Assisted reproduction (IVF): triggers controlled ovarian stimulation for oocyte retrieval. - Precocious puberty: delays further sexual development by suppressing gonadotropin release. - Uterine fibroids: alleviates symptoms through estrogen suppression.

What are the side effects of Triptorelin?

Adverse reactions to triptorelin vary with the indication and duration of therapy.

Common Side Effects: - Hot flashes: transient warmth and sweating episodes. - Injection site reactions: redness, swelling or mild pain. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Nausea: mild gastrointestinal upset. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, myocardial infarction or stroke. - Bone loss: decreased bone mineral density leading to osteoporosis. - Severe allergic reaction: anaphylaxis, angioedema or urticaria. - Hormonal crisis: acute adrenal insufficiency or adrenal crisis. - Pituitary apoplexy: sudden hemorrhage into the pituitary gland. - Liver dysfunction: marked elevation of transaminases.

What precautions apply to Triptorelin?

When using triptorelin, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate history of hypertension, heart disease or stroke risk. - Bone health monitoring: baseline densitometry and periodic follow‑up for osteoporosis risk. - Hormonal status: assess baseline testosterone/estradiol levels and adjust therapy accordingly. - Pregnancy and lactation: contraindicated in pregnant or nursing women; effective contraception required. - Drug interactions: review concomitant medications that affect hormone metabolism. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

What does Triptorelin interact with?

Triptorecin may interact with other medicines that influence hormonal pathways or cardiovascular function.

Major Interactions (Avoid): - Anticoagulants: increased bleeding risk when combined with GnRH‑induced endothelial changes. - CYP3A4 inhibitors: may alter hormone metabolism and increase systemic exposure.

Moderate Interactions (Monitor Closely): - Steroids: additive effects on bone density loss. - Thyroid hormone replacement: may require dose adjustment due to altered hormone dynamics. - Antihypertensive agents: blood pressure response may be modified. - Antidepressants (SSRIs): potential for heightened mood‑related side effects. - Diuretics: electrolyte balance may shift with hormonal changes.

Frequently asked questions

What conditions is Pamorelin La used to treat?+
Pamorelin La contains triptorelin, a GnRH agonist approved for hormone‑dependent conditions such as advanced prostate cancer, endometriosis, uterine fibroids, precocious puberty and for triggering ovarian stimulation in assisted reproductive technology cycles.
How does triptorelin work in the body?+
Triptorelin mimics natural GnRH and binds to pituitary GnRH receptors. Continuous exposure desensitises these receptors, sharply reducing luteinising hormone and follicle‑stimulating hormone release, which in turn lowers circulating testosterone and estradiol levels, providing the hormonal suppression needed for its therapeutic effects.
What is the usual dose of Pamorelin La?+
The specific dose and administration schedule of Pamorelin La are determined by the prescribing clinician based on the indication, patient characteristics and treatment goals. Healthcare professionals should follow the product’s prescribing information and adjust dosing as required.
Is Pamorelin La safe to use during pregnancy or breastfeeding?+
Pamorelin La is contraindicated in pregnancy and breastfeeding because it suppresses sex‑steroid production, which can harm fetal development and affect milk production. Effective contraception is required for women of child‑bearing potential during treatment.
How do I order Pamorelin La from GNH USA?+
To order Pamorelin La, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.
How does Pamorelin La compare with other GnRH agonists?+
Pamorelin La (triptorelin) is chemically similar to other GnRH agonists such as leuprolide and goserelin, offering comparable efficacy in hormone suppression. Differences may lie in dosing frequency, formulation (e.g., depot versus short‑acting), and manufacturer‑specific excipients, which can influence convenience and patient preference.
What are the recommended storage conditions for Pamorelin La?+
Store Pamorelin La below 25 °C in its original container, protecting it from moisture and direct light. Do not freeze the product, and keep it out of reach of children.
How is Pamorelin La administered?+
Pamorelin La is supplied as a sterile powder that must be reconstituted with the provided diluent and administered by subcutaneous or intramuscular injection according to the prescribing clinician’s instructions.
What are the most serious risks associated with Pamorelin La?+
Serious risks include cardiovascular events such as hypertension or stroke, severe bone loss leading to osteoporosis, allergic reactions like anaphylaxis, and rare hormonal crises. Patients should be monitored regularly for these potential complications.
Who should not use Pamorelin La?+
Pamorelin La is contraindicated in individuals with known hypersensitivity to triptorelin or any formulation components, pregnant or nursing women, and patients with uncontrolled cardiovascular disease or severe osteoporosis without appropriate management.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Triptorelin
Route
Intramuscular Use
Manufacturer
Ipsen Pharma Gmbh
Origin
EU

Related products

Arvekap

Arvekap

Triptorelin

Ipsen M.E.P.E.
EU
Arvekap

Arvekap

Triptorelin

Ipsen M.E.P.E.
EU
Arvekap

Arvekap

Triptorelin

Ipsen M.E.P.E.
EU
Arvekap

Arvekap

Triptorelin

Ipsen M.E.P.E.
EU